Tyra Biosciences, Inc.
- Biotech or pharma, therapeutic R&D
The only FGFR3-specific inhibitor in development for NMIBC and Skeletal Conditions (phase 2s now open for enrollment)
The only FGFR3-specific inhibitor in development for NMIBC and Skeletal Conditions (phase 2s now open for enrollment)